81 related articles for article (PubMed ID: 27397576)
1. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
2. Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia Patients.
Aldapt MB; Al-Mashdali AF; Obeidat K; Chandra P; Yassin M
Oncology; 2024; 102(4):380-388. PubMed ID: 37848004
[TBL] [Abstract][Full Text] [Related]
3. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Başcı S; Ata N; Altuntaş F; Yiğenoğlu TN; Dal MS; Korkmaz S; Namdaroğlu S; Baştürk A; Hacıbekiroğlu T; Doğu MH; Berber İ; Dal K; Erkurt MA; Turgut B; Çağlayan M; Ayvalı MO; Çelik O; Ülgü MM; Birinci Ş;
J Oncol Pharm Pract; 2020 Oct; 26(7):1676-1682. PubMed ID: 32854573
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
Iurlo A; Cattaneo D; Bucelli C; Spallarossa P; Passamonti F
Curr Treat Options Oncol; 2023 Dec; 24(12):1720-1738. PubMed ID: 38047977
[TBL] [Abstract][Full Text] [Related]
5. Chronic Myeloid Leukemia in Renal Transplantation Patients in the Era of Tyrosine Kinase Inhibitors: A Case Report and Review of the Literature.
Murt A; Bayram B; Yılmaz U; Seyahi N; Eşkazan AE
Nephron; 2024 Apr; ():1-6. PubMed ID: 38574488
[TBL] [Abstract][Full Text] [Related]
6. Challenges in Management of Pediatric Chronic Myeloid Leukemia (pCML) in the Low-Middle Income Countries (LMICs): Insights from an International CML Foundation (iCMLf) Multi-National Survey.
Roy Moulik N; Harriss-Buchan A; Saglio G; Suttorp M
Pediatr Hematol Oncol; 2024 May; 41(4):290-295. PubMed ID: 38229452
[TBL] [Abstract][Full Text] [Related]
7. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Goldberg SL; Cortes JE; Gambacorti-Passerini C; Hehlmann R; Khoury HJ; Michallet M; Paquette RL; Simonsson B; Zyczynski T; Foreman A; Abruzzese E; Andorsky D; Beeker A; Cony-Makhoul P; Hansen R; Lomaia E; Olavarria E; Mauro MJ
Am J Hematol; 2017 Nov; 92(11):1214-1223. PubMed ID: 28815757
[TBL] [Abstract][Full Text] [Related]
10. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Hoehn D; Cortes JE; Medeiros LJ; Jabbour EJ; Hidalgo JE; Kanagal-Shamanna R; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl(Suppl):S86-92. PubMed ID: 27521332
[TBL] [Abstract][Full Text] [Related]
11. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
12. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions.
Borriello A; Caldarelli I; Bencivenga D; Stampone E; Perrotta S; Oliva A; Della Ragione F
Oncotarget; 2017 Jan; 8(3):5540-5565. PubMed ID: 27750212
[TBL] [Abstract][Full Text] [Related]
14. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interactions with imatinib: An observational study.
Récoché I; Rousseau V; Bourrel R; Lapeyre-Mestre M; Chebane L; Despas F; Montastruc JL; Bondon-Guitton E
Medicine (Baltimore); 2016 Oct; 95(40):e5076. PubMed ID: 27749579
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis.
Liu Y; Fang B; Jiang J; Wang P
J Cancer Res Ther; 2016 Oct; 12(Supplement):23-26. PubMed ID: 27721246
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
18. Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia.
Liu J; Tan X; Ma YY; Liu Y; Gao L; Gao L; Kong P; Peng XG; Zhang X; Zhang C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e349-e358. PubMed ID: 31076372
[TBL] [Abstract][Full Text] [Related]
19. Correlation of MicroRNA 17-92 Cluster Host Gene (MIR17HG) Polymorphisms With Susceptibility and Prognosis for Multiple Myeloma.
Wu H; Huang T; Ye Z; Fu X; Hu K; Yang X
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e359-e366. PubMed ID: 31029648
[TBL] [Abstract][Full Text] [Related]
20. Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.
Ye F; Li N
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e259-e265. PubMed ID: 31023595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
